SVP Chad Gassert sold 14,736 shares at avg $89.06; all 5 prior ANIP sales were well-timed at 90d mark
Chad Gassert, SVP of Corporate Development & Strategy, executed 2 separate sales totaling 14,736 shares for $1,312,434.94 (blended average $89.06) on 2025-11-12 and 2025-11-13, reducing his holdings by 8.5% to 158,490 shares. His timing pattern at ANI Pharmaceuticals is notable: all 5 of his prior sales at this ticker were well-timed at the 90-day mark, with negative 90-day returns following each sale—indicating he has consistently sold before subsequent declines. The stock is currently -15.0% from its 52-week high and -6.8% over the past 30 days, trading at $84.02. Given his demonstrated track record of well-timed exits at this specific ticker and the company's current elevated valuation (P/E 50.61, market cap $2.1B), his sustained pattern of selling deserves investor scrutiny.
SVP Chad Gassert sold 20,000 ANIP shares at $86.97 (total $1.7M); stock now 0.3% below 52-week high after surging +47.9% in 90 days.
Chad Gassert, SVP of Corporate Development & Strategy at ANI Pharmaceuticals, sold 20,000 shares at $86.97 on August 15, reducing his holdings by 10.4%. The sale occurred near the 52-week high ($90.00), with the stock trading just -0.3% below that peak and having rallied +47.9% over the prior 90 days. His prior 5 trades at ANIP show 4 of 5 were well-timed at the 90-day mark, suggesting a track record of selling before downturns at this specific ticker. However, context matters: ANI delivered +26.2% annual revenue growth and $8.5M net income on $211.4M quarterly revenue, though the company was unprofitable on a full-year basis, indicating operational instability. The timing—a substantial insider sale near all-time highs after a steep rally—warrants attention to whether management sees valuation stretched relative to underlying financial performance.
SVP Chad Gassert sold 20,000 ANIP shares at $63.44 on 2024-07-01 (post-transaction: 193.2K shares held)
Chad Gassert, SVP of Corporate Development & Strategy, sold 20,000 shares of ANI Pharmaceuticals at $63.44, reducing his holdings by 9.4% to 193,226 shares. The stock has since declined to $62.64 (current), down 3.5% over 30 days and 6.8% over 90 days, placing it 10.1% below its 52-week high. His same-ticker history at ANIP shows 5 prior sales with mixed timing outcomes: 2 of the 3 measurable transactions resulted in negative 90-day returns (well-timed sells at the 2024-04-01 and 2023-10-02 dates), though the most recent ANIP sale on 2024-06-03 outcomes remain unmeasurable. Across his broader cross-ticker track record, his 50% well-timed rate and average 90-day return of -0.4% suggest neither consistent early warning nor reliable misjudgment. The company's fundamentals remain solid—revenue of $137.4M, net income of $18.2M, and 53.9% annual revenue growth—though the elevated P/E of 42.90 reflects current market valuations. The pattern of repeated insider sales in recent months at a strategically senior executive level warrants observation as the stock navigates a post-high-volatility period.
